Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.
JPMorgan Chase & Co. and its affiliates have notified Mesoblast Limited that they have ceased to be a substantial holder in the company as of 22 January 2026, following a series of transactions involving securities lending, rehypothecation under prime brokerage agreements, and principal trading activities across several JPMorgan entities. The change reduces JPMorgan’s voting power in Mesoblast and may slightly alter the company’s institutional shareholder profile, although no broader strategic or operational implications were disclosed in the notice.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company focused on developing allogeneic cellular medicines, particularly mesenchymal lineage cell therapies, targeting inflammatory diseases, cardiovascular conditions, and other serious and chronic illnesses in markets such as the United States and Australia.
YTD Price Performance: -1.47%
Average Trading Volume: 4,104,358
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.46B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.